ANP has been shown to act as an autocrine/paracrine modulator of cardiac hypertrophy and remodelling.17, 18, 19 We have earlier demonstrated that C‐ANP4‐23, an agonist that interacts specifically with NPR‐C and small peptide fragments of cytoplasmic domain of NPR‐C with Gi activator sequences inhibited vasoactive peptide‐induced hypertrophy of A10 VSMC.20 However, whether C‐ANP4‐23 could also attenuate hypertrophy of VSMC from SHR, a rat model that exhibits cardiac hypertrophy remains obscure. Here, GNAI1 is linked to cardiac hypertrophy.